Clinical studies continue to support the use of psilocybin for mental health. A study from JAMA Psychiatry just found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR, for example. New York Univ. found “Psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreased in cancer-related demoralization and hopelessness, improved spiritual well-being.”
The Beckley Foundation said, “Psilocybin was well-tolerated and induced rapid and lasting reduction in the severity of depressive symptoms.” Helping, the US FDA says psilocybin is a “breakthrough therapy” for clinical depression.
In addition, pharmaceutical companies could begin to enter the psychedelic space, according to Wired. “As patents on many conventional antidepressants begin to expire – and public and regulatory opinion regarding psychedelics is changing – 2021 will be the time that psychedelic therapy casts a spotlight on the limitations of current mental-health care treatments, and highlights a bold alternative.”